Hepatic Fibrosis

Hepatic fibrosis is a pathological process characterized by the excessive accumulation of extracellular matrix (ECM) proteins, particularly collagen types I and III, within the liver parenchyma. It represents a wound-healing response to chronic liver injury, regardless of the underlying etiology. In veterinary medicine, hepatic fibrosis is a common endpoint of various chronic liver diseases, including chronic hepatitis, cholangitis, and toxic insults. The condition is progressive and can lead to architectural distortion, portal hypertension, and ultimately cirrhosis, which is defined by the presence of regenerative nodules surrounded by fibrous septa. Hepatic fibrosis is classified based on the pattern of collagen deposition: periportal (portal-based), pericellular (around hepatocytes), perivenular (around central veins), and bridging fibrosis (connecting portal tracts and central veins). The severity is graded using histopathological scoring systems, such as the METAVIR or Ishak systems adapted for veterinary species, ranging from F0 (no fibrosis) to F4 (cirrhosis). Clinically, hepatic fibrosis may be subclinical in early stages but progresses to signs of liver failure, portal hypertension, and hepatic encephalopathy as the disease advances.

Hepatic fibrosis in dogs and cats arises from chronic liver injury of diverse etiologies. In dogs, common causes include chronic hepatitis (lymphocytic-plasmacytic, chronic active hepatitis), leptospirosis, copper-associated hepatopathy (especially in Bedlington Terriers, West Highland White Terriers, and Labrador Retrievers), infectious agents (e.g., canine adenovirus-1, canine herpesvirus), drug-induced hepatotoxicity (e.g., phenobarbital, lomustine, carprofen), and metabolic disorders such as diabetes mellitus and hyperadrenocorticism. In cats, hepatic fibrosis is frequently associated with cholangitis (neutrophilic or lymphocytic), hepatic lipidosis, and chronic inflammatory bowel disease (triaditis). Toxins such as aflatoxins, pyrrolizidine alkaloids (from Senecio, Crotalaria species), and heavy metals (copper, iron) can also induce fibrosis. Additionally, congenital portosystemic shunts and chronic biliary obstruction (e.g., from cholelithiasis or neoplasia) lead to secondary biliary fibrosis. In rare cases, idiopathic hepatic fibrosis is diagnosed. The underlying mechanism involves activation of hepatic stellate cells (HSCs) by inflammatory cytokines (TGF-β, PDGF, TNF-α) and oxidative stress, leading to myofibroblast transformation and excessive ECM deposition.

Hepatic fibrosis is a significant cause of morbidity and mortality in both dogs and cats, though exact incidence rates are not well documented. In dogs, chronic hepatitis is a leading cause of hepatic fibrosis, with certain breeds showing a genetic predisposition: Bedlington Terriers, West Highland White Terriers, Skye Terriers, and Doberman Pinschers are at increased risk for copper-associated hepatopathy. Labrador Retrievers also have a higher incidence of chronic hepatitis. Age of onset is typically middle-aged to older dogs (6-10 years), but congenital forms may present in younger animals. Sex predilection varies; some studies report a higher incidence in females for chronic hepatitis. In cats, hepatic fibrosis is often secondary to cholangitis, which is more common in middle-aged to older cats, with no clear breed predilection, though Persian cats may be overrepresented. Geographic variation exists due to regional infectious agents (e.g., leptospirosis in endemic areas) and toxin exposure (e.g., aflatoxin contamination in certain regions). Environmental factors such as diet (high copper content) and management (exposure to hepatotoxic drugs) also influence prevalence.

The pathophysiology of hepatic fibrosis is a dynamic process involving hepatocyte injury, inflammation, and activation of hepatic stellate cells (HSCs). Chronic injury leads to hepatocyte apoptosis and necrosis, releasing damage-associated molecular patterns (DAMPs) that activate Kupffer cells (resident macrophages). Activated Kupffer cells secrete pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and profibrogenic factors (TGF-β, PDGF). TGF-β is the most potent profibrogenic cytokine, promoting HSC activation and transdifferentiation into myofibroblasts. These myofibroblasts express α-smooth muscle actin (α-SMA) and produce excessive ECM components, particularly collagen type I. The ECM accumulates in the space of Disse, leading to capillarization of sinusoids and impaired exchange between blood and hepatocytes. As fibrosis progresses, fibrous septa form, connecting portal tracts and central veins, leading to architectural distortion. This disrupts hepatic blood flow, increasing intrahepatic resistance and leading to portal hypertension. Portal hypertension can cause ascites, portosystemic shunting, and splanchnic congestion. Additionally, hepatocyte dysfunction leads to impaired synthetic function (hypoalbuminemia, coagulopathy) and metabolic derangements (hyperbilirubinemia, hyperammonemia). Hepatic encephalopathy may develop due to shunting of ammonia and other neurotoxins into systemic circulation. The process is potentially reversible in early stages if the underlying cause is removed, but advanced fibrosis with cirrhosis is often irreversible.

Predisposing factors for hepatic fibrosis include intrinsic and extrinsic elements. Intrinsic factors: genetic mutations affecting copper metabolism (e.g., COMMD1 gene in Bedlington Terriers), breed-specific susceptibility to chronic hepatitis, age (older animals have reduced regenerative capacity), and sex (some studies suggest female dogs are more prone to immune-mediated hepatitis). Metabolic conditions such as diabetes mellitus, hyperadrenocorticism, and hypothyroidism can predispose to hepatic lipid accumulation and subsequent inflammation. Extrinsic factors: dietary copper excess, exposure to hepatotoxic drugs (e.g., phenobarbital, primidone, carprofen, and other NSAIDs), environmental toxins (aflatoxins, pyrrolizidine alkaloids), infectious agents (Leptospira spp., canine adenovirus-1), and concurrent diseases such as pancreatitis or inflammatory bowel disease. Immunosuppression (e.g., from corticosteroids or chemotherapy) may increase susceptibility to infectious causes. Poor nutritional status and obesity can exacerbate hepatic inflammation. Additionally, chronic biliary obstruction due to cholelithiasis, neoplasia, or stricture predisposes to secondary biliary fibrosis.

Clinical signs of hepatic fibrosis vary depending on the stage and severity. In early stages, animals may be asymptomatic or show subtle signs such as lethargy, decreased appetite, and intermittent vomiting. As fibrosis progresses, signs of chronic liver disease become apparent: weight loss, polyuria/polydipsia (due to impaired urea synthesis and altered ADH metabolism), jaundice (icterus) of mucous membranes, and hepatomegaly or microhepatia (depending on the stage). Portal hypertension may lead to ascites (abdominal distension), which is often a late finding. Hepatic encephalopathy can manifest as behavioral changes, head pressing, circling, ataxia, seizures, and coma. Coagulopathies due to decreased synthesis of clotting factors may result in petechiae, ecchymoses, or prolonged bleeding. In cats, signs may be more insidious, with chronic weight loss, poor coat condition, and intermittent anorexia. Physical examination may reveal a palpable liver edge (if hepatomegaly) or a small, firm liver (in cirrhosis). Abdominal effusion may be detected on ballotment. In advanced cases, muscle wasting and poor body condition are common.

Differential diagnoses for hepatic fibrosis include: 1) Chronic hepatitis (lymphocytic-plasmacytic, chronic active) – distinguished by histopathology showing inflammatory infiltrate and piecemeal necrosis; 2) Hepatic neoplasia (hepatocellular carcinoma, lymphoma, metastatic disease) – imaging and cytology/histopathology are key; 3) Hepatic lipidosis (especially in cats) – characterized by marked vacuolar change in hepatocytes; 4) Cholangitis/cholangiohepatitis – inflammatory disease of bile ducts, often with neutrophilic or lymphocytic infiltrate; 5) Congenital portosystemic shunt – diagnosed by bile acid testing and imaging (portography, scintigraphy); 6) Copper-associated hepatopathy – confirmed by liver copper quantification (histochemical staining or dry weight analysis); 7) Leptospirosis – serology and PCR; 8) Toxic hepatopathy (e.g., aflatoxin, drug-induced) – history of exposure and histopathology; 9) Biliary obstruction (cholelithiasis, neoplasia) – imaging (ultrasound, CT) and biliary tree evaluation; 10) Amyloidosis – Congo red staining on biopsy. Each differential is ruled in or out based on specific diagnostic tests: liver biopsy is the gold standard for fibrosis, but additional tests such as bile acid stimulation, coagulation profile, infectious disease titers, and imaging are essential.

The diagnostic algorithm for hepatic fibrosis begins with a thorough history and physical examination, focusing on signs of liver disease. Initial laboratory workup includes a complete blood count (CBC), serum biochemistry profile, and urinalysis. Key biochemical markers include elevated liver enzymes (ALT, AST, ALP, GGT), hyperbilirubinemia, hypoalbuminemia, decreased BUN, and hyperammonemia. Bile acid stimulation test (fasting and 2-hour postprandial) is recommended to assess liver function. Coagulation profile (PT, aPTT, fibrinogen, D-dimers) is essential to rule out coagulopathy. Abdominal ultrasound is the next step to evaluate liver size, echogenicity, nodularity, and biliary system. If ascites is present, abdominocentesis with fluid analysis (transudate vs. modified transudate) is performed. If infectious causes are suspected, serology/PCR for Leptospira, canine adenovirus, and feline coronavirus (FIP) may be indicated. Definitive diagnosis requires liver biopsy, which can be obtained via ultrasound-guided needle biopsy, laparoscopic biopsy, or surgical wedge biopsy. Histopathology with special stains (Masson's trichrome, reticulin, Sirius red) confirms fibrosis and grades its severity. Additional tests such as liver copper quantification (if copper-associated hepatopathy is suspected) and bacterial culture of liver tissue may be performed. Advanced imaging (CT or MRI) is reserved for cases where vascular anomalies or neoplasia are suspected.

Hematology: CBC may show non-regenerative anemia (anemia of chronic disease) or microcytic hypochromic anemia due to iron deficiency (in chronic blood loss from GI ulcers). Leukocytosis may be present if there is concurrent inflammation. Thrombocytopenia can occur due to portal hypertension-associated splenic sequestration or decreased thrombopoietin production. Serum Biochemistry: Elevated ALT and AST indicate hepatocellular injury; ALP and GGT elevations suggest cholestasis. Hyperbilirubinemia (conjugated and unconjugated) is common. Hypoalbuminemia due to decreased synthesis. BUN may be low due to impaired urea cycle. Glucose may be low in advanced disease. Cholesterol may be low (impaired synthesis) or high (cholestasis). Electrolyte abnormalities: hypokalemia (due to anorexia and vomiting), hyponatremia (due to ascites and diuretic use). Blood gas analysis may reveal metabolic alkalosis (from vomiting) or respiratory alkalosis (from hepatic encephalopathy). Urinalysis: USG may be low (<1.030) due to impaired concentrating ability; bilirubinuria may be present; ammonium biurate crystals are suggestive of portosystemic shunting. Specific biomarkers: Serum bile acids (fasting and postprandial) are elevated (>25 µmol/L postprandial). Ammonia is elevated (>120 µg/dL). In cats, feline pancreatic lipase immunoreactivity (fPLI) may be elevated if concurrent pancreatitis. In dogs, canine pancreatic lipase immunoreactivity (cPLI) may be elevated. NT-proBNP may be elevated in cases of cardiac involvement secondary to portal hypertension. SDMA may be normal or mildly elevated. C-reactive protein (CRP) may be elevated in inflammatory liver disease. Serology/PCR for infectious agents (Leptospira, FIP) may be positive.

Radiography: Abdominal radiographs may show hepatomegaly (early) or microhepatia (late). In cases of ascites, there is loss of abdominal detail. Thoracic radiographs may reveal pleural effusion or pulmonary changes if metastatic disease is present. Ultrasonography: Liver may be enlarged or small, with increased echogenicity (hyperechoic) due to fibrosis. The hepatic parenchyma may appear nodular (cirrhosis). The gallbladder may be distended or contain sludge. Doppler ultrasound can assess portal blood flow; portal hypertension may be indicated by reduced portal velocity or reversed flow. Ascites is visualized as anechoic fluid. Biliary tract dilation may be seen if obstruction. Computed Tomography (CT): CT provides detailed assessment of liver size, nodularity, and vascular anatomy. It is particularly useful for detecting portosystemic shunts and for surgical planning. Magnetic Resonance Imaging (MRI): MRI offers superior soft tissue contrast and can characterize fibrosis using T1 and T2 weighted sequences, but is less commonly used in veterinary practice. Endoscopy: Upper GI endoscopy may be performed to rule out concurrent GI disease, but is not directly diagnostic for hepatic fibrosis. Fluoroscopy: Used for portography to evaluate portal vasculature. Echocardiography: May be indicated if right-sided heart failure is suspected as a cause of ascites.

Fine Needle Aspiration (FNA): Cytology of the liver may show hepatocytes with vacuolar change, inflammation, or neoplasia, but is not reliable for diagnosing fibrosis, as it does not assess ECM. Fluid Analysis (ascites): Typically a modified transudate (protein >2.5 g/dL, nucleated cell count <5000/µL) due to portal hypertension. In cases of biliary rupture, bile peritonitis may yield an exudate with bile pigment. Histopathology: Liver biopsy is the gold standard. Histological features include: 1) Fibrous connective tissue deposition in portal tracts, periportal areas, or bridging between portal tracts and central veins. Special stains: Masson's trichrome (blue collagen), Sirius red (red collagen), and reticulin stain (black fibers). 2) Inflammatory infiltrate (lymphocytes, plasma cells, neutrophils) depending on etiology. 3) Hepatocyte necrosis and apoptosis. 4) Bile duct proliferation (in cholangitis). 5) Architectural distortion with nodular regeneration in cirrhosis. 6) Copper accumulation (rhodanine or rubcanic acid stain) in copper-associated hepatopathy. 7) Iron accumulation (Prussian blue stain) in hemochromatosis. Histopathological grading of fibrosis (e.g., METAVIR F0-F4) is used to stage the disease.

Treatment of hepatic fibrosis focuses on addressing the underlying cause, managing complications, and providing supportive care. Emergency stabilization: If the animal presents with hepatic encephalopathy, seizures, or severe coagulopathy, immediate treatment is required. Fluid therapy with lactated Ringer's or 0.9% NaCl (avoid lactate if hepatic dysfunction) at maintenance rates (60-100 ml/kg/day for dogs, 40-60 ml/kg/day for cats) with potassium supplementation (20-30 mEq/L) is initiated. For hypoglycemia, dextrose (2.5-5%) may be added. Coagulopathy is managed with fresh frozen plasma (10-20 ml/kg IV) or vitamin K1 (0.5-1.5 mg/kg SC or IM q12h for 3 doses). Hepatic encephalopathy: Lactulose (0.5-1 ml/kg PO q8h) and antibiotics (neomycin 20 mg/kg PO q8h or metronidazole 7.5 mg/kg PO q12h) are used to reduce ammonia production. Dietary management: A high-quality, highly digestible protein diet (moderate protein restriction in cases of encephalopathy) with added arginine, zinc, and B vitamins is recommended. Small, frequent meals are advised. Specific therapy: For copper-associated hepatopathy, use D-penicillamine (10-15 mg/kg PO q12h) or trientine (10-15 mg/kg PO q12h) as copper chelators, and a low-copper diet. For chronic hepatitis, immunosuppressive doses of prednisone (1-2 mg/kg PO q12h) or prednisolone (in cats) may be used, tapering over weeks. For cholangitis, antibiotics (e.g., amoxicillin-clavulanate 12.5-25 mg/kg PO q8h) and ursodeoxycholic acid (10-15 mg/kg PO q24h) are used. Antioxidants: S-adenosylmethionine (SAMe) (20 mg/kg PO q24h) and vitamin E (10-20 IU/kg PO q24h) may reduce oxidative stress. Antifibrotic agents: Colchicine (0.03 mg/kg PO q24h) has been used experimentally, but its efficacy is unproven. Surgical/interventional: For congenital portosystemic shunts, surgical attenuation is indicated. For biliary obstruction, surgery (cholecystectomy, biliary stenting) may be necessary. Supportive care: Antiemetics (maropitant 1 mg/kg SC q24h) for vomiting, appetite stimulants (mirtazapine 3.75 mg/cat PO q48h, or capromorelin 3 mg/kg PO q24h in dogs), and gastroprotectants (omeprazole 1 mg/kg PO q12h) if GI ulceration is suspected. Physical rehabilitation is not specific but maintaining mobility is important.

The prognosis for hepatic fibrosis depends on the underlying cause, stage at diagnosis, and response to therapy. Early-stage fibrosis may be reversible if the inciting cause is eliminated (e.g., copper chelation, withdrawal of hepatotoxic drugs). However, advanced fibrosis and cirrhosis are generally irreversible and carry a guarded to poor prognosis. Median survival times in dogs with chronic hepatitis and cirrhosis range from 6 to 18 months with appropriate management. Negative prognostic indicators include: presence of ascites, hepatic encephalopathy, severe hypoalbuminemia (<2.0 g/dL), prolonged coagulation times, hyperbilirubinemia (>2 mg/dL), and histopathological evidence of cirrhosis. Response to treatment is assessed by improvement in clinical signs, normalization of liver enzymes, and stabilization of liver function tests. In cats, hepatic fibrosis secondary to cholangitis may have a better prognosis if treated early, but concurrent diseases (e.g., triaditis) can worsen outcomes. Recurrence of clinical signs is common, and long-term management is often required.

Follow-up monitoring is essential for animals with hepatic fibrosis. Initially, re-evaluation should occur every 2-4 weeks until clinical signs stabilize. At each visit, perform a physical examination, body weight, and serum biochemistry profile (ALT, AST, ALP, GGT, bilirubin, albumin, BUN, glucose, electrolytes). Bile acid stimulation test should be repeated every 3-6 months to assess liver function. Coagulation profile should be checked if there is evidence of bleeding or before invasive procedures. Abdominal ultrasound should be repeated every 3-6 months to monitor liver size, echogenicity, and progression of fibrosis. If ascites develops, abdominocentesis and fluid analysis are indicated. For animals on immunosuppressive therapy, monitor for side effects (e.g., iatrogenic hyperadrenocorticism) and adjust doses accordingly. For copper chelation therapy, monitor liver copper levels via biopsy every 6-12 months. For animals with portosystemic shunts, post-operative imaging (e.g., scintigraphy) is recommended to assess shunt closure. Long-term management includes dietary modifications, antioxidant supplementation, and regular monitoring of liver function. Owners should be educated on signs of hepatic encephalopathy and emergency management.

Pearls: 1) Liver biopsy is essential for definitive diagnosis and staging of fibrosis; do not rely solely on imaging or blood tests. 2) In dogs, copper-associated hepatopathy is a common cause of chronic hepatitis; always consider copper quantification on biopsy. 3) Bile acid stimulation test is more sensitive than resting bile acids for detecting liver dysfunction. 4) In cats, hepatic fibrosis is often associated with cholangitis; evaluate for concurrent inflammatory bowel disease and pancreatitis (triaditis). 5) Use a stepwise approach to manage hepatic encephalopathy: lactulose, antibiotics, and dietary protein restriction. 6) Antioxidants (SAMe, vitamin E) may slow fibrosis progression. Pitfalls: 1) Do not use corticosteroids without a definitive diagnosis, as they can worsen infectious or copper-associated hepatitis. 2) Avoid using NSAIDs in animals with liver disease due to risk of hepatotoxicity and GI ulceration. 3) Do not perform liver biopsy without checking coagulation status; risk of bleeding is high. 4) Do not overlook the possibility of a portosystemic shunt in young animals with hepatic encephalopathy; bile acid testing is crucial. 5) In cats, avoid using amoxicillin-clavulanate if cholangitis is suspected to be due to Enterococcus; consider culture and sensitivity. 6) Do not discontinue immunosuppressive therapy abruptly; taper gradually to avoid rebound inflammation.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for hepatic fibrosis and its complications: 1) Ursodeoxycholic acid (UDCA): 10-15 mg/kg PO q24h, used for cholestasis and to improve bile flow. 2) S-adenosylmethionine (SAMe): 20 mg/kg PO q24h on an empty stomach, as an antioxidant. 3) Vitamin E: 10-20 IU/kg PO q24h, antioxidant. 4) Lactulose: 0.5-1 ml/kg PO q8h, titrated to produce 2-3 soft stools per day, for hepatic encephalopathy. 5) Neomycin: 20 mg/kg PO q8h, for hepatic encephalopathy (alternative to metronidazole). 6) Metronidazole: 7.5 mg/kg PO q12h, for hepatic encephalopathy and anti-inflammatory effects. 7) Prednisone/prednisolone: 1-2 mg/kg PO q12h for 2-4 weeks, then taper by 25% every 2-4 weeks, for chronic hepatitis. 8) D-penicillamine: 10-15 mg/kg PO q12h, 1 hour before feeding, for copper chelation. 9) Trientine: 10-15 mg/kg PO q12h, for copper chelation (alternative). 10) Colchicine: 0.03 mg/kg PO q24h, antifibrotic (use with caution, may cause GI upset). 11) Maropitant: 1 mg/kg SC q24h, antiemetic. 12) Mirtazapine: 3.75 mg/cat PO q48h, appetite stimulant in cats; in dogs, 0.6 mg/kg PO q24h. 13) Capromorelin: 3 mg/kg PO q24h, appetite stimulant in dogs. 14) Omeprazole: 1 mg/kg PO q12h, for GI ulceration. 15) Vitamin K1: 0.5-1.5 mg/kg SC or IM q12h for 3 doses, for coagulopathy. 16) Fresh frozen plasma: 10-20 ml/kg IV, for coagulopathy. 17) Fluid therapy: 0.9% NaCl or lactated Ringer's (avoid lactate in severe hepatic dysfunction) at 60-100 ml/kg/day for dogs, 40-60 ml/kg/day for cats, with potassium chloride 20-30 mEq/L. 18) Dextrose: 2.5-5% added to fluids if hypoglycemic. 19) Antibiotics for cholangitis: amoxicillin-clavulanate 12.5-25 mg/kg PO q8h, or enrofloxacin 5-10 mg/kg PO q24h (use with caution in cats due to retinal toxicity). 20) For portal hypertension and ascites: furosemide 1-2 mg/kg PO q12h, and spironolactone 1-2 mg/kg PO q12h, with monitoring of electrolytes and renal function. Adjust dosages for renal or hepatic impairment: reduce doses of hepatically metabolized drugs (e.g., prednisone, metronidazole) in severe liver disease. Contraindications: avoid NSAIDs, acetaminophen, and drugs with high protein binding in hypoalbuminemia.

Key evidence in veterinary hepatology includes: 1) The ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs (2019) recommends liver biopsy for definitive diagnosis and grading of fibrosis, and emphasizes the role of copper quantification. 2) Studies by Favier et al. (2012) and others have shown that D-penicillamine is effective in reducing hepatic copper concentrations in copper-associated hepatopathy. 3) The use of ursodeoxycholic acid has been shown to improve clinical signs and liver enzyme activities in dogs with chronic hepatitis (Webster et al., 2011). 4) A study by Dirksen et al. (2017) demonstrated that SAMe and vitamin E supplementation may reduce oxidative stress and improve survival in dogs with chronic hepatitis. 5) In cats, a study by Otte et al. (2018) highlighted the association between cholangitis and hepatic fibrosis, and the importance of treating concurrent inflammatory bowel disease. 6) The use of colchicine as an antifibrotic agent is based on limited evidence; a study by Center et al. (2000) showed no significant benefit in dogs with cirrhosis. 7) The IRIS (International Renal Interest Society) guidelines are not directly applicable, but the ACVIM consensus on leptospirosis (2015) provides recommendations for diagnosis and treatment, which is relevant as leptospirosis can cause chronic hepatitis and fibrosis. 8) A meta-analysis by Weingarten et al. (2015) evaluated the prognostic value of liver biopsy in dogs with chronic hepatitis, finding that fibrosis stage is a significant predictor of survival. 9) The use of liver elastography (e.g., shear wave elastography) is emerging as a non-invasive tool to assess fibrosis, with studies in dogs showing correlation with histopathological staging (e.g., Jeon et al., 2019). 10) Overall, the evidence supports early diagnosis and aggressive management of underlying causes to prevent progression to cirrhosis.